Nonnarcotic Analgesics and Hypertension

American Journal of Cardiology

Volumn 97, Issue 9 SUPPL. 1, 2006, Pages 10-16

  Gaziano, J Michael ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETORICOXIB; HYDROCHLOROTHIAZIDE; IBUPROFEN; INDOMETACIN; LISINOPRIL; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; ROFECOXIB; SULINDAC;

ARTHRITIS; ARTICLE; BLOOD PRESSURE REGULATION; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORRELATION ANALYSIS; DOSE KIDNEY FUNCTION RELATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; FLUID RETENTION; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PAIN; PERIPHERAL EDEMA; PRESCRIPTION; PRIORITY JOURNAL; SODIUM RETENTION; STROKE;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PRESSURE; HUMANS; HYPERTENSION; PAIN;

EID: 33646491588     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.02.018     Document Type: Article

References (47)

1. IMS Health. Commonly requested therapeutic class and product information. Available at: http://www.imshealth.com/ims/portal/front/indexC/0,2772,6599_71488591_0, 0.html. Accessed April 3, 2006.
2. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J., and VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
3. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson W.F., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 284 (2000) 1247-1255
4. Singh G., Ramey D.R., Morfeld D., Shi H., Hatoum H.T., and Fries J.F. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. a prospective observational cohort study. Arch Intern Med 156 (1996) 1530-1536
5. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (1999) 1888-1899
6. Gurwitz J.H., Avorn J., Bohn R.L., Glynn R.J., Monane M., and Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 272 (1994) 781-786
7. Houston M.C. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 90 suppl 5A (1991) 42S-47S
8. Johnson A.G., Nguyen T.V., and Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121 (1994) 289-300
9. Pope J.E., Anderson J.J., and Felson D.T. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153 (1993) 477-484
10. Centers for Disease Control and Prevention. Prevalence of self-reported arthritis or chronic joint symptoms among adults-United States, 2001. MMWR Morb Mortal Wkly Rep 51 (2002) 948-950
11. Fields L.E., Burt V.L., Cutler J.A., Hughes J., Roccella E.J., and Sorlie P. The burden of adult hypertension in the United States 1999 to 2000. a rising tide. Hypertension 44 (2004) 398-404
12. Cushman W.C. The burden of uncontrolled hypertension. morbidity and mortality associated with disease progression. J Clin Hypertens (Greenwich) 5 suppl 2 (2003) 14-22
13. MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J., Abbott R., Godwin J., Dyer A., and Stamler J. Blood pressure, stroke, and coronary heart disease, part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335 (1990) 765-774
14. Bleumink G.S., Feenstra J., Sturkenboom M.C.J.M., and Stricker B.H.C. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 63 (2003) 525-534
15. Catella-Lawson F., McAdam B., Morrison B.W., Kapoor S., Kujubu D., Antes L., Lasseter K.C., Quan H., Gertz B.J., and Fitzgerald G.A. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289 (1999) 735-741
16. Frishman W.H. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol 89 suppl (2002) 18D-25D
17. Patrono C., and Dunn M.J. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 32 (1987) 1-12
18. Rossat J., Maillard M., Nussberger J., Brunner H.R., and Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66 (1999) 76-84
19. Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegeman R.A., Pak J.Y., Gildehaus D., Miyashiro J.M., Penning T.D., Seibert K., Isakson P.C., and Stallings W.C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. [letter]. Nature 384 (1996) 644-648
20. 2 synthase-1. Nature 367 (1994) 243-249
21. Whelton A., Schulman G., Wallemark C., Drower E.J., Isakson P.C., Verburg K.M., and Geis G.S. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 160 (2000) 1465-1470
22. Zhao S.Z., Reynolds M.W., Lekowith J., Whelton A., and Arellano F.M. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther 23 (2001) 1478-1491
23. Whelton A., Maurath C.J., Verburg K.M., and Geis G.S. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 7 (2000) 159-175
24. Morlans M., Laporte J.R., Vidal X., Cabeza D., and Stolley P.D. End-stage renal disease and non-narcotic analgesics. a case-control study. Br J Clin Pharmacol 30 (1990) 717-723
25. Perneger T.V., Whelton P.K., and Klag M.J. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 331 (1994) 1675-1679
26. Pommer W., Bronder E., Greiser E., Helmert U., Jesdinsky H.J., Klimpel A., Borner K., and Molzahn M. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 9 (1989) 403-412
27. Sandler D.P., Burr F.R., and Weinberg C.R. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 115 (1991) 165-172
28. Sandler D.P., Smith J.C., Weinberg C.R., Buckalew Jr. V.M., Dennis V.W., Blythe W.B., and Burgess W.P. Analgesic use and chronic renal disease. N Engl J Med 320 (1989) 1238-1243
29. Curhan G.C., Knight E.L., Rosner B., Hankinson S.E., and Stampfer M.J. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 164 (2004) 1519-1524
30. Kurth T., Glynn R.J., Walker A.M., Rexrode K.M., Buring J.E., Stampfer M.J., Hennekens C.H., and Gaziano J.M. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis 42 (2003) 234-244
31. Rexrode K.M., Buring J.E., Glynn R.J., Stampfer M.J., Youngman L.D., and Gaziano J.M. Analgesic use and renal function in men. JAMA 286 (2001) 315-321
32. Kurth T., Hennekens C.H., Sturmer T., Sesso H.D., Glynn R.J., Buring J.E., and Gaziano M. Analgesic use and risk of subsequent hypertension in apparently healthy men. Arch Intern Med 165 (2005) 1903-1909
33. Colina-Chourio J.A., Godoy-Godoy N., and Avila-Hernańdez R.M. Role of prostaglandins in hypertension. J Hum Hypertens 14 suppl 1 (2000) S16-S19
34. Chrischilles E.A., and Wallace R.B. Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population. J Gerontol 48 (1993) M91-M96
35. Gurwitz J.H., Everitt D.E., Monane M., Glynn R.J., Choodnovskiy I., Beaudet M.P., and Avorn J. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J Gerontol A Biol Sci Med Sci 51 (1996) M74-M79
36. Johnson A.G., Simons L.A., Simons J., Friedlander Y., and McCallum J. Non-steroidal anti-inflammatory drugs and hypertension in the elderly. a community-based cross-sectional study. Br J Clin Pharmacol 35 (1993) 455-459
37. Dedier J., Stampfer M.J., Hankinson S.E., Willett W.C., Speizer F.E., and Curhan G.C. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 40 (2002) 604-608
38. Forman J.P., Stampfer M.J., and Curhan G.C. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 46 (2005) 500-507
39. Wolfe F., Zhao S., Reynolds M., and Pettitt D. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J Rheumatol 31 (2004) 1143-1151
40. Solomon D.H., Schneeweiss S., Levin R., and Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 44 (2004) 140-145
41. Aw T.J., Haas S.J., Liew D., and Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165 (2005) 490-496
42. Whelton A., Fort J.G., Puma J.A., Normandin D., Bello A.E., Verburg K.M., and SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function. a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 8 (2001) 85-95
43. Vioxx prescribing information (2000), Merck & Co, Inc, Whitehouse Station, NJ
44. Celebrex prescribing information (2000), Pharmacia, Peapack, NJ
45. Sowers J.R., White W.B., Pitt B., Whelton A., Simon L.S., Winer N., Kivitz A., van Ingen H., Brabant T., Fort J.G., and Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 165 (2005) 161-168
46. Whelton A., White W.B., Bello A.E., Puma J.A., Fort J.G., and SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90 (2002) 959-963
47. White W.B., Kent J., Taylor A., Verburg K.M., Lefkowith J.B., and Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 39 (2002) 929-934